Cyclopharm (ASX:CYC) Quality Rank


ASX:CYC Cyclopharm Ltd ASX:CYC
45 GF Score
Price A$0.48
GF Value A$0.83
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cyclopharm Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Cyclopharm Quality Rank Related Terms

ASX:CYC
45GF Score
Cyclopharm Ltd ASX:CYC
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cyclopharm (ASX:CYC) Overvalued in 2026?

Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued. The current stock price of A$0.48 is trading 42.8% below its estimated GF Value™ of A$0.83. GuruFocus considers Cyclopharm to be Possible Value Trap.

Key valuation signals for ASX:CYC:

  • Quality Rank:
  • GF Value™: A$0.83 vs. price of A$0.48 (42.8% below fair value)
  • GF Score™: 45/100 with 7 warning signs

No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cyclopharm Business Description

Address 1 The Crescent, Unit 4, Kingsgrove, Sydney, NSW, AUS, 2208
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
45GF Score

Get the complete analysis for ASX:CYC

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.48
Price
A$0.83
GF Value